Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) (EASE LID)

This study has been completed.
Information provided by (Responsible Party):
Adamas Pharmaceuticals, Inc. Identifier:
First received: May 9, 2014
Last updated: February 15, 2017
Last verified: February 2017

This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once nightly at bedtime for the treatment of levodopa induced dyskinesia (LID) in subjects with Parkinson's disease (PD). The novel pharmacokinetic profile of ADS-5102 is expected to achieve i) maximal concentrations in the early morning through mid-day, when LID can be troublesome, and ii) lower concentrations in the evening, potentially reducing the negative impact of amantadine on sleep. This pharmacokinetic profile could enable higher doses to be tolerated with a once-nightly ER formulation than can be tolerated with an immediate-release formulation. The once-nightly dosing regimen may also provide enhanced convenience and compliance.

In a previous clinical study, ADS-5102 met its primary endpoint; LID was significantly reduced as measured by the change in UDysRS score over 8 weeks vs. placebo.

Condition Intervention Phase
Levodopa Induced Dyskinesia (LID)
Parkinson's Disease
Drug: ADS-5102
Other: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)

Resource links provided by NLM:

Further study details as provided by Adamas Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Change in the Unified Dyskinesia Rating Scale (UDysRS) score [ Time Frame: Baseline to week 12 ]

Secondary Outcome Measures:
  • Change in the standardized PD home diary (ON time without dyskinesia, ON time with troublesome dyskinesia, OFF time) [ Time Frame: Baseline to week 12 and week 24 ]
  • Change in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) [ Time Frame: Baseline to week 12 and week 24 ]
  • Clinician's Global Impression of Change in overall PD symptoms [ Time Frame: Baseline to week 12 and week 24 ]
  • Change in the Unified Dyskinesia Rating Scale (UDysRS) Score [ Time Frame: Baseline to week 24 ]

Enrollment: 126
Study Start Date: May 2014
Study Completion Date: December 2015
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ADS-5102
ADS-5102 (amantadine HCl extended release)
Drug: ADS-5102
Oral capsules to be administered once nightly at bedtime, for 25 weeks
Other Name: amantadine HCl extended release
Placebo Comparator: Placebo
Other: Placebo
Oral capsules to be administered once nightly at bedtime, for 25 weeks


Ages Eligible for Study:   30 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed a current IRB/REB/IEC-approved informed consent form
  • Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria
  • On a stable regimen of antiparkinson's medications for at least 30 days prior to screening, including a levodopa preparation administered not less than three times daily, and willing to continue the same doses and regimens during study participation
  • Following diary training, the subject is willing and able to understand and complete the 24-hour PD home diary (caregiver/study partner assistance allowed)
  • Any other current and allowed prescription/non-prescription medications and/or nutritional supplements taken regularly must have been at a stable dose and regimen for at least 30 days prior to screening, and subject must be willing to continue the same doses and regimens during study participation (this criterion does not apply to medications that are being taken pre-study only on an as-needed basis)

Exclusion Criteria:

  • History of neurosurgical intervention related to Parkinson's disease (e.g. deep brain stimulation)
  • History of seizures within 2 years prior to screening
  • History of stroke or transient ischemic attack (TIA) within 2 years prior to screening
  • History of cancer within 5 years prior to screening, with the following exceptions: adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer
  • Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination (MMSE) score of less than 24 during screening
  • If female, is pregnant or lactating
  • If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment.
  • Treatment with an investigational drug or device within 30 days prior to screening
  • Treatment with an investigational biologic within 6 months prior to screening
  • Current participation in another clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02136914

  Show 46 Study Locations
Sponsors and Collaborators
Adamas Pharmaceuticals, Inc.
Study Director: Clinical Trials Director Adamas Pharmaceuticals, Inc.
  More Information

Responsible Party: Adamas Pharmaceuticals, Inc. Identifier: NCT02136914     History of Changes
Other Study ID Numbers: ADS-AMT-PD301
Study First Received: May 9, 2014
Last Updated: February 15, 2017

Keywords provided by Adamas Pharmaceuticals, Inc.:
Levodopa Induced Dyskinesia

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Neurologic Manifestations
Signs and Symptoms
Antiparkinson Agents
Anti-Dyskinesia Agents
Antiviral Agents
Anti-Infective Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents processed this record on May 23, 2017